MAPT and Alzheimer disease: In line with this, it has been shown that a disruption in O-GlcNAcylation equilibrium poses serious risks in disease conditions like Alzheimer’s disease, where O-GlcNAcylation changes alter phosphorylation levels of Tau protein, which is involved in the pathogenesis of the disease (30, 31).